A phage display nanobody discovery service uses a nanobody library, iterative target selection, and screening to identify candidate binders for further evaluation. A typical project moves from target and assay planning through library selection, candidate screening, sequence confirmation, and delivery of agreed materials and data. For veterinary medicine, the target may be a pathogen protein, toxin, or animal biomarker, but a research binder is not automatically a validated diagnostic or therapeutic reagent. At NBbiolab, we work with buyers to define the intended use and deliverables before project scope is finalized.
If you want to learn more, please visit our website.
This guide is for veterinary diagnostics developers, animal health researchers, biotechnology companies, and procurement teams considering custom nanobody discovery. It is useful if you need to understand what happens during a project, what information to provide, and what to request from a supplier. It can also help teams compare proposals that differ in library source, screening strategy, characterization, or final materials. The right scope depends on the target, assay, and intended downstream application.
Nanobodies are single-domain antibody fragments derived from camelid heavy-chain antibodies or designed from related frameworks. A VHH domain is commonly around 12–15 kDa, substantially smaller than a conventional full-length antibody. Its antigen-binding surface is formed by three complementarity-determining regions, or CDRs, supported by the framework.
In phage display, genetic information for a nanobody is linked to a coat protein on a bacteriophage. This connection allows a displayed nanobody to be selected for binding to an immobilized or cell-associated target, while the corresponding sequence can be recovered from the phage. Repeated selection and screening can enrich target-reactive candidates, but binding in an initial assay does not by itself establish specificity, function, or suitability in an animal or clinical setting.
The project begins with a review of the target, species relevance, and intended use. For veterinary applications, clarify whether the nanobody is for research, assay development, pathogen detection, or another purpose, and identify the animal species and sample matrix where relevant. Provide target sequence or construct details, available protein, known homologs, and any assay constraints. These details help shape the selection and counter-screening plan.
The target’s format can influence discovery outcomes. A purified recombinant protein may be suitable for selection, while a membrane protein, complex, or conformational epitope may require a different presentation strategy. Buyers should share information about tags, expression system, purity, oligomeric state, and whether the target’s native conformation matters. When feasible, a supplier can review the antigen plan before the project starts, but antigen suitability cannot be guaranteed without experimental assessment.
The supplier selects an appropriate nanobody library and exposes phage to the target under defined conditions. Non-binding phage are removed during washing, and retained phage are recovered for subsequent rounds. A project commonly uses about 2–4 selection rounds, although the number and conditions may be adjusted based on enrichment, target behavior, and assay results. Counter-selection against related proteins, tags, or background materials may be included when specificity is important.
After selection, individual clones are screened using an agreed assay, such as an immunoassay or another target-binding format. Screening helps identify candidates for further work; it is not equivalent to complete characterization. Buyers should confirm what the screening assay measures, what controls are included, and whether screening is performed against the target in the same form planned for downstream use. For veterinary diagnostic development, testing against relevant species homologs or sample-related interferents may need to be scoped separately.
Link to NBbiolab
Promising clones can be sequence-verified and, if included in the scope, expressed as soluble nanobodies for additional testing. Characterization may include binding confirmation, comparative screening, or other agreed assays. Affinity, specificity, expression yield, stability, and functional activity are distinct attributes; one result should not be treated as proof of all the others. Ask the supplier to state which measurements are included and which are optional.
Deliverables vary by service package and contract. A proposal may include sequence information for selected candidates, screening results, purified nanobody material, or project documentation. Confirm the number of candidates, material format and quantity, data file formats, and whether plasmids, expression constructs, or additional characterization are included. We recommend documenting acceptance criteria and ownership or permitted use of project materials before work begins.
For veterinary diagnostics, a candidate may be investigated as a capture or detection reagent, provided its binding behavior is evaluated in the intended assay format. For research on animal pathogens, the target should reflect the relevant species or strain, and cross-reactivity should be considered when related organisms are present. Biomarker projects should account for the target’s form in the intended sample, which may differ from a purified protein used during selection. In every case, downstream validation in the relevant assay and sample type remains the buyer’s responsibility unless explicitly included in the service scope.
A clear proposal should distinguish discovery from validation and list optional work separately. This is particularly important when the goal is a veterinary diagnostic reagent, because performance may depend on sample matrix, target variation, and assay design. Compare suppliers on the transparency of their workflow and deliverables, not only on the headline price. Request written confirmation of what is included before submitting valuable antigen or starting a purchase order.
Pricing depends on factors such as library choice, target complexity, antigen preparation, counter-screening, candidate expression, and characterization. Minimum antigen quantities and acceptable sample formats are project-specific, so buyers should request requirements for their actual target rather than assume a universal amount. Lead time also varies with selection strategy, screening workload, and whether additional expression or characterization is requested. We recommend asking for a milestone-based schedule and identifying which steps could affect it.
A phage display nanobody discovery service typically covers target planning, library selection, enrichment, clone screening, and delivery of agreed candidate materials or data. The most important purchasing decision is to align the target format, veterinary use case, specificity requirements, and characterization plan before the project begins. The approximate 12–15 kDa size of a VHH, its three CDR loops, and the commonly used 2–4 selection rounds describe general features of the technology, not guaranteed project outcomes. Each target and service scope should be assessed individually.
To evaluate fit with NBbiolab, prepare your target information, intended application, available antigen details, and preferred deliverables. We can discuss a suitable discovery and screening scope, clarify optional validation work, and provide a project proposal for review. Contact our team with your target and requirements to begin a technical discussion.
For more information, please visit Phage Display Nanobody Discovery Service.